 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK
May 02, 2012
Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - Competing Pharmas Race to Pinpoint Markers Beyond KRAS for Personalized Colorectal Cancer Rx
April 21, 2010 / Pharmacogenomics Reporter - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter - BMS, Amgen's Trials in Wild-Type KRAS Patients Could Clarify PGx Labeling for CRC Drugs
December 7, 2011 / Pharmacogenomics Reporter - ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter